Tocilizumab in Treatment for Patients with COVID-19 - Reply

Carlo Salvarani; Marco Massari; Nicola Facciolongo

doi:10.1001/jamainternmed.2021.0404

Tocilizumab in Treatment for Patients with COVID-19 - Reply

Carlo Salvarani, Marco Massari, Nicola Facciolongo

Arcispedale Santa Maria Nuova

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	1019-1020
Number of pages	2
Journal	JAMA Internal Medicine
Volume	181
Issue number	7
DOIs	https://doi.org/10.1001/jamainternmed.2021.0404
Publication status	Published - Jul 2021

ASJC Scopus subject areas

Internal Medicine

Access to Document

10.1001/jamainternmed.2021.0404

Cite this

@article{2656facb97fc4783925f995aa3f31283,

title = "Tocilizumab in Treatment for Patients with COVID-19 - Reply",

author = "Carlo Salvarani and Marco Massari and Nicola Facciolongo",

year = "2021",

month = jul,

doi = "10.1001/jamainternmed.2021.0404",

language = "English",

volume = "181",

pages = "1019--1020",

journal = "JAMA Internal Medicine",

issn = "2168-6106",

publisher = "American Medical Association",

number = "7",

}

TY - JOUR

T1 - Tocilizumab in Treatment for Patients with COVID-19 - Reply

AU - Salvarani, Carlo

AU - Massari, Marco

AU - Facciolongo, Nicola

PY - 2021/7

Y1 - 2021/7

UR - http://www.scopus.com/inward/record.url?scp=85103588229&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85103588229&partnerID=8YFLogxK

U2 - 10.1001/jamainternmed.2021.0404

DO - 10.1001/jamainternmed.2021.0404

M3 - Letter

C2 - 33818607

AN - SCOPUS:85103588229

VL - 181

SP - 1019

EP - 1020

JO - JAMA Internal Medicine

JF - JAMA Internal Medicine

SN - 2168-6106

IS - 7

ER -

Tocilizumab in Treatment for Patients with COVID-19 - Reply

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this